Archives

  • Volume 3, Issue 2, Summer 2024

    • Mantle Cell Lymphoma: Evolving Frontline Treatment Strategies
    • Therapy for Myelodysplastic Syndromes Beyond the Front Line in 2024 in Canada
    • Management of Chronic Myeloid Leukemia that is Intolerant or Resistant to Front-line Treatment
    • High-Risk Myeloma: Definitions and Treatments
    • Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia After BTK Inhibitor and/or BCL-2 Inhibitor Failure

  • Volume 3, Issue 1, Spring 2024

    • Front-line Management of Follicular Lymphoma 
    • Burkitt Lymphoma: The Curable Challenge
    • Follicular Non-Hodgkin Lymphoma: First Relapse and Beyond
    • Systemic Mastocytosis: Diagnosis and Management in 2024
    • Maintenance Therapy for CD20+ Indolent Lymphoma: Who Should Receive Maintenance?

  • Special Supplement, February 2024

    • Bruton Tyrosine Kinase Inhibitors for B-Cell Malignancies

  • Special Supplement, January 2024

  • Special Supplement, January 2024

      • Maintenance Therapy in Acute Myeloid Leukemia: A New Standard of Care

  • Special Supplement, November 2023

    • MDS Clearpath: An internet-based educational algorithm for the work-up, diagnosis and management of patients with myelodysplastic syndromes from the Canadian Consortium on MDS

  • Volume 2, Issue 3, October 2023

    • Bispecific antibodies and chimeric antigen receptor (CAR) T-cell therapy for indolent lymphoma
    • The role of FDG-PET scanning and PET-adapted therapy in the primary treatment of Hodgkin lymphoma: A primer for clinicians
    • Monoclonal gammopathy of clinical and undetermined significance
    • Frontline treatment of aggressive B-cell lymphoma
    • Chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma: The evolving Canadian landscape

  • Special Supplement, July 2023

    • Roundtable discussion: Navigating challenging treatment decisions in relapsed and refractory multiple myeloma (RRMM)

  • Volume 2, Issue 2, June 2023

    • Review: Coronavirus disease (COVID-19) in patients with hematologic malignancy
    • Cellular therapy in CLL/iNHL: Therapeutic agents in the pipeline
    • Evolving role of novel therapies in myeloma: T-cell engagers and antibody-drug conjugates
    • Acute myeloid leukemia induction in the age of novel therapeutic agents
    • Initiating venetoclax treatment: Clinical practice pearls

  • Volume 2, Issue 1, March 2023

    • Frontline management of transplant-ineligible newly diagnosed multiple myeloma (TINDMM) in Canada
    • Controversies and current practices in CNS relapse of diffuse large B-cell lymphoma
    • Management of limited stage Hodgkin lymphoma
    • Tyrosine kinase inhibitors for the frontline management of CML: An overview
    • Venetoclax-based lower-intensity regimens for acute myeloid leukemia: Clinical pearls for a new standard of care

  • Special Supplement, March 2023

    • A review of the mechanism of action, safety, and efficacy of selinexor in multiple myeloma

  • Special Supplement, December 2022

    • Updates in the treatment of mantle cell lymphoma: A Canadian expert framework

  • Special Supplement, November 2022

    • Expert clinical framework report: Management of adverse events related to novel therapies for relapsed/refractory multiple myeloma (RRMM)

  • Volume 1, Issue 3, November 2022

    • Moving beyond chemotherapy in the management of follicular lymphoma
    • Hereditary hematologic malignancies: A Canadian perspective
    • The evolving treatment landscape of higher-risk MDS
    • Chronic Myeloid Leukemia: Who should get a treatment-free trial and how?
    • Evolving strategies in T-cell lymphoma

  • Special Supplement, October 2022

    • Panel Discussion: Treatment options for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) patients

  • Volume 1, Issue 2, July 2022

    • Immunotherapy in Hodgkin lymphoma: Current and evolving roles
    • Tailoring therapy in Waldenström Macroglobulinemia
    • Multiple myeloma management: What comes after lenalidomide-based therapy?
    • Chimeric antigen receptor T-cell therapy for relapsed and refractory large B-cell lymphoma: A Canadian perspective
    • With great power comes great responsibility: Managing side effects of novel treatments in chronic lymphocytic leukemia (CLL)

  • Special Supplement, June 2022

    • Safety and tolerability of Bruton's tyrosine kinase inhibitors in the treatment of Waldenström macroglobulinemia

  • Volume 1, Issue 1, March 2022

    • Next-generation sequencing for myeloid malignancies: Progress and practical applications
    • Management of follicular lymphoma at first relapse
    • Myeloproliferative neoplasms in 2022: A concise review
    • Diagnosis and treatment of AL amyloidosis in 2022
    • To transplant or not to transplant in multiple myeloma
    • Emerging therapeutic agents in the treatment of relapsed or refractory diffuse large B cell lymphoma